|
| 37380560 | Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. | Eur Urol | 2024 |
| 37966367 | Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. | Clin Cancer Res | 2024 |
| 37775361 | Reply to Kentaro Inamura's Letter to the Editor re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.023. | Eur Urol | 2024 |
| 36754853 | Comparison of clinicopathological characteristics, gene expression profiles, mutational analysis, and clinical outcomes of pure and mixed small-cell carcinoma of the bladder. | Histopathology | 2023 |
| 37596191 | Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605. | Eur Urol | 2023 |
| 37662238 | Combined Mek inhibition and <i>Pparg</i> activation Eradicates Muscle Invasive Bladder cancer in a Mouse Model of BBN-induced Carcinogenesis. | bioRxiv | 2023 |
| 37087309 | Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314. | Eur Urol Oncol | 2023 |
| 37414705 | Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695). | Eur Urol | 2023 |
| 36820243 | Enfortumab Vedotin-related Cutaneous Toxicity and Radiographic Response in Patients with Urothelial Cancer: A Single-center Experience and Review of the Literature. | Eur Urol Open Sci | 2023 |
| 36517188 | The Many Faces of Muscle-Invasive Bladder Cancer: Histopathological and Molecular Characterization. | Semin Radiat Oncol | 2023 |
| 36717286 | A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study. | Eur Urol | 2023 |
| 34801336 | Corrigendum to "Identification of Differential Tumor Subtypes of T1 Bladder Cancer" [Eur. Urol. 78 (2020) 533-537]. | Eur Urol | 2022 |
| 35847448 | Lentiviral interferon: A novel method for gene therapy in bladder cancer. | Mol Ther Oncolytics | 2022 |
| 35699798 | Race reporting and disparities regarding clinical trials in bladder cancer: a systematic review. | Cancer Causes Control | 2022 |
| 35811851 | Erratum: The origin of bladder cancer from mucosal field effects. | iScience | 2022 |
| 35618577 | Characterizing molecular subtypes of high-risk non-muscle-invasive bladder cancer in African American patients. | Urol Oncol | 2022 |
| 34933753 | Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. | Eur Urol | 2022 |
| 35169141 | Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancer. | Nat Commun | 2022 |
| 34736796 | A Molecular Inquiry into the Role of Antibody-Drug Conjugates in Bacillus Calmette-Guérin-exposed Non-muscle-invasive Bladder Cancer. | Eur Urol | 2022 |
| 34731491 | BCG invokes superior STING-mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer. | J Pathol | 2022 |
| 34426176 | Gender-specific Stratification of Survival Following Immune Checkpoint Inhibitor Therapy Based on Intratumoral Expression of a B cell Gene Signature. | Eur Urol Oncol | 2022 |
| 31563523 | Circulating Tumor Cell and Circulating Tumor DNA Assays Reveal Complementary Information for Patients with Metastatic Urothelial Cancer. | Eur Urol Oncol | 2021 |
| 33881933 | Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma. | J Urol | 2021 |
| 33653802 | Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study. | J Immunother Cancer | 2021 |
| 33487562 | "Advancing bladder preservation: Biomarkers, decision-making, and therapy". | Urol Oncol | 2021 |
| 33568346 | A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). | Clin Cancer Res | 2021 |
| 33901032 | Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes. | Appl Immunohistochem Mol Morphol | 2021 |
| 33846523 | A miRNA signature predicts benefit from addition of hypoxia-modifying therapy to radiation treatment in invasive bladder cancer. | Br J Cancer | 2021 |
| 33500355 | Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216). | Clin Cancer Res | 2021 |
| 34607803 | γδ T Cells Support Antigen-Specific αβ T cell-Mediated Antitumor Responses during BCG Treatment for Bladder Cancer. | Cancer Immunol Res | 2021 |
| 34514028 | Unique somatic variants in DNA from urine exosomes of individuals with bladder cancer. | Mol Ther Methods Clin Dev | 2021 |
| 34021032 | Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes. | J Immunother Cancer | 2021 |
| 34131332 | 100 years of Bacillus Calmette-Guérin immunotherapy: from cattle to COVID-19. | Nat Rev Urol | 2021 |
| 34129819 | Molecular subtypes of upper tract urothelial cancer: Setting the stage for precision therapy. | Cancer Cell | 2021 |
| 34148797 | New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer - What do we understand so far? | Urol Oncol | 2021 |
| 33958145 | Molecular Biology of Bladder Cancer: Potential Implications for Therapy. | Hematol Oncol Clin North Am | 2021 |
| 32061548 | Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile. | Eur Urol Oncol | 2021 |
| 33358150 | Small Cell Bladder Cancer Response to Second-line and Beyond Checkpoint Inhibitor Therapy: Retrospective Experience. | Clin Genitourin Cancer | 2021 |
| 32858539 | Urothelial Carcinoma In Situ of the Bladder: Correlation of CK20 Expression With Adaptive Immune Resistance, Response to BCG Therapy, and Clinical Outcome. | Appl Immunohistochem Mol Morphol | 2021 |
| 32814637 | Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. | Eur Urol | 2021 |
| 31411999 | Combined Next-generation Sequencing and Flow Cytometry Analysis for an Anti-PD-L1 Partial Responder over Time: An Exploration of Mechanisms of PD-L1 Activity and Resistance in Bladder Cancer. | Eur Urol Oncol | 2021 |
| 31383572 | Does it matter whether a T1 high-grade tumor is molecularly classified? | Eur Urol Oncol | 2021 |
| 31395481 | Does Variant Histology Change Management of Non-muscle-invasive Bladder Cancer? | Eur Urol Oncol | 2021 |
| 32235944 | Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes. | Nat Rev Urol | 2020 |
| 31712383 | Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. | Clin Cancer Res | 2020 |
| 32037144 | Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434-5. | Eur Urol | 2020 |
| 33457262 | Update on bladder cancer molecular subtypes. | Transl Androl Urol | 2020 |
| 32684305 | Identification of Differential Tumor Subtypes of T1 Bladder Cancer. | Eur Urol | 2020 |
| 32842545 | Mutational Landscape and Environmental Effects in Bladder Cancer. | Int J Mol Sci | 2020 |
| 32122956 | TCF21 Promotes Luminal-Like Differentiation and Suppresses Metastasis in Bladder Cancer. | Mol Cancer Res | 2020 |